Enzo Biochem Issues Statement On Recent Stock Activity.Business Editors FARMINGDALE, NY--(BUSINESS WIRE)--Feb. 3, 2000 Enzo Biochem, Inc. (NYSE NYSE See: New York Stock Exchange :ENZ) today issued the following statement: &uot;The Company knows of no reason to account for the activity in the stock. As the Company made clear at its annual meeting last month and in a release issued this past Tuesday regarding a presentation at this week's Retroviruses and Opportunistic Infections Opportunistic infections Infections that cause a disease only when the host's immune system is impaired. The classic opportunistic infection never leads to disease in the normal host. Conference in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] , it has made a critical first step forward in the development of a gene medicine for the treatment of HIV-1 infection. The Company also reported that its HGTV HGTV Home and Garden Television 43 vector has successfully delivered antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). genes efficiently and quickly to non-growing cells outside the human body, and following transduction transduction, in genetics: see recombination. Transduction (bacteria) A mechanism for the transfer of genetic material between cells. , the genetically engineered blood cells have survived in circulation, and continue to produce antisense RNA. The Company, following a peer review, also was a recipient of a grant to expand its hepatitis B virus clinical trial. In addition, the Company's business of producing and marketing DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. labeling and detection products for diagnostic and genome research continues to expand. We have never been more optimistic regarding the Company's outlook.&uot; Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Except for historical information, the matters discussed in this news release may be considered &uot;forward-looking&uot; statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion